Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms

Janet Douglas, Marites L. Panis, Edmund Ho, Kuei Ying Lin, Steve H. Krawczyk, Deborah M. Grant, Ruby Cai, Swami Swaminathan, Xiaowu Chen, Tomas Cihlar

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Here we present data on the mechanism of action of VP-14637 and JNJ-2408068 (formerly R-170591), two small-molecule inhibitors of respiratory syncytial virus (RSV). Both inhibitors exhibited potent antiviral activity with 50% effective concentrations (EC50S) of 1.4 and 2.1 nM, respectively. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50 = 5.4 and 0.9 nM, respectively). Several drug-resistant RSV variants were selected in vitro in the presence of each compound. All selected viruses exhibited significant cross-resistance to both inhibitors and contained various single amino acid substitutions in two distinct regions of the viral F protein, the heptad repeat 2 (HR2; mutations D486N, E487D, and F488Y), and the intervening domain between HR1 and HR2 (mutation K399I and T400A). Studies using [3H]VP-14637 revealed a specific binding of the compound to RSV-infected cells that was efficiently inhibited by JNJ-2408068 (50% inhibitory concentration = 2.9 nM) but not by the HR2-derived peptide T-118. Further analysis using a transient T7 vaccinia expression system indicated that RSV F protein is sufficient for this interaction. F proteins containing either the VP-14637 or JNJ-2408068 resistance mutations exhibited greatly reduced binding of [3H]VP-14637. Molecular modeling analysis suggests that both molecules may bind into a small hydrophobic cavity in the inner core of F protein, interacting simultaneously with both the HR1 and HR2 domains. Altogether, these data indicate that VP-14637 and JNJ-2408068 interfere with RSV fusion through a mechanism involving a similar interaction with the F protein.

Original languageEnglish (US)
Pages (from-to)2460-2466
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume49
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

2((2-((1-(2-aminoethyl)-4-piperidinyl)amino)-4-methyl-1H-benzimidazol-1-yl)methyl)-6-methyl-3-pyridinol
Respiratory Syncytial Viruses
Mutation
Proteins
Peptide T
Vaccinia
Cell Fusion
Viral Proteins
Amino Acid Substitution
Inhibitory Concentration 50
Antiviral Agents
VP 14637

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. / Douglas, Janet; Panis, Marites L.; Ho, Edmund; Lin, Kuei Ying; Krawczyk, Steve H.; Grant, Deborah M.; Cai, Ruby; Swaminathan, Swami; Chen, Xiaowu; Cihlar, Tomas.

In: Antimicrobial Agents and Chemotherapy, Vol. 49, No. 6, 06.2005, p. 2460-2466.

Research output: Contribution to journalArticle

Douglas, J, Panis, ML, Ho, E, Lin, KY, Krawczyk, SH, Grant, DM, Cai, R, Swaminathan, S, Chen, X & Cihlar, T 2005, 'Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms', Antimicrobial Agents and Chemotherapy, vol. 49, no. 6, pp. 2460-2466. https://doi.org/10.1128/AAC.49.6.2460-2466.2005
Douglas, Janet ; Panis, Marites L. ; Ho, Edmund ; Lin, Kuei Ying ; Krawczyk, Steve H. ; Grant, Deborah M. ; Cai, Ruby ; Swaminathan, Swami ; Chen, Xiaowu ; Cihlar, Tomas. / Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. In: Antimicrobial Agents and Chemotherapy. 2005 ; Vol. 49, No. 6. pp. 2460-2466.
@article{2c6869f6f54049f6aced255027a8e37a,
title = "Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms",
abstract = "Here we present data on the mechanism of action of VP-14637 and JNJ-2408068 (formerly R-170591), two small-molecule inhibitors of respiratory syncytial virus (RSV). Both inhibitors exhibited potent antiviral activity with 50{\%} effective concentrations (EC50S) of 1.4 and 2.1 nM, respectively. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50 = 5.4 and 0.9 nM, respectively). Several drug-resistant RSV variants were selected in vitro in the presence of each compound. All selected viruses exhibited significant cross-resistance to both inhibitors and contained various single amino acid substitutions in two distinct regions of the viral F protein, the heptad repeat 2 (HR2; mutations D486N, E487D, and F488Y), and the intervening domain between HR1 and HR2 (mutation K399I and T400A). Studies using [3H]VP-14637 revealed a specific binding of the compound to RSV-infected cells that was efficiently inhibited by JNJ-2408068 (50{\%} inhibitory concentration = 2.9 nM) but not by the HR2-derived peptide T-118. Further analysis using a transient T7 vaccinia expression system indicated that RSV F protein is sufficient for this interaction. F proteins containing either the VP-14637 or JNJ-2408068 resistance mutations exhibited greatly reduced binding of [3H]VP-14637. Molecular modeling analysis suggests that both molecules may bind into a small hydrophobic cavity in the inner core of F protein, interacting simultaneously with both the HR1 and HR2 domains. Altogether, these data indicate that VP-14637 and JNJ-2408068 interfere with RSV fusion through a mechanism involving a similar interaction with the F protein.",
author = "Janet Douglas and Panis, {Marites L.} and Edmund Ho and Lin, {Kuei Ying} and Krawczyk, {Steve H.} and Grant, {Deborah M.} and Ruby Cai and Swami Swaminathan and Xiaowu Chen and Tomas Cihlar",
year = "2005",
month = "6",
doi = "10.1128/AAC.49.6.2460-2466.2005",
language = "English (US)",
volume = "49",
pages = "2460--2466",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms

AU - Douglas, Janet

AU - Panis, Marites L.

AU - Ho, Edmund

AU - Lin, Kuei Ying

AU - Krawczyk, Steve H.

AU - Grant, Deborah M.

AU - Cai, Ruby

AU - Swaminathan, Swami

AU - Chen, Xiaowu

AU - Cihlar, Tomas

PY - 2005/6

Y1 - 2005/6

N2 - Here we present data on the mechanism of action of VP-14637 and JNJ-2408068 (formerly R-170591), two small-molecule inhibitors of respiratory syncytial virus (RSV). Both inhibitors exhibited potent antiviral activity with 50% effective concentrations (EC50S) of 1.4 and 2.1 nM, respectively. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50 = 5.4 and 0.9 nM, respectively). Several drug-resistant RSV variants were selected in vitro in the presence of each compound. All selected viruses exhibited significant cross-resistance to both inhibitors and contained various single amino acid substitutions in two distinct regions of the viral F protein, the heptad repeat 2 (HR2; mutations D486N, E487D, and F488Y), and the intervening domain between HR1 and HR2 (mutation K399I and T400A). Studies using [3H]VP-14637 revealed a specific binding of the compound to RSV-infected cells that was efficiently inhibited by JNJ-2408068 (50% inhibitory concentration = 2.9 nM) but not by the HR2-derived peptide T-118. Further analysis using a transient T7 vaccinia expression system indicated that RSV F protein is sufficient for this interaction. F proteins containing either the VP-14637 or JNJ-2408068 resistance mutations exhibited greatly reduced binding of [3H]VP-14637. Molecular modeling analysis suggests that both molecules may bind into a small hydrophobic cavity in the inner core of F protein, interacting simultaneously with both the HR1 and HR2 domains. Altogether, these data indicate that VP-14637 and JNJ-2408068 interfere with RSV fusion through a mechanism involving a similar interaction with the F protein.

AB - Here we present data on the mechanism of action of VP-14637 and JNJ-2408068 (formerly R-170591), two small-molecule inhibitors of respiratory syncytial virus (RSV). Both inhibitors exhibited potent antiviral activity with 50% effective concentrations (EC50S) of 1.4 and 2.1 nM, respectively. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50 = 5.4 and 0.9 nM, respectively). Several drug-resistant RSV variants were selected in vitro in the presence of each compound. All selected viruses exhibited significant cross-resistance to both inhibitors and contained various single amino acid substitutions in two distinct regions of the viral F protein, the heptad repeat 2 (HR2; mutations D486N, E487D, and F488Y), and the intervening domain between HR1 and HR2 (mutation K399I and T400A). Studies using [3H]VP-14637 revealed a specific binding of the compound to RSV-infected cells that was efficiently inhibited by JNJ-2408068 (50% inhibitory concentration = 2.9 nM) but not by the HR2-derived peptide T-118. Further analysis using a transient T7 vaccinia expression system indicated that RSV F protein is sufficient for this interaction. F proteins containing either the VP-14637 or JNJ-2408068 resistance mutations exhibited greatly reduced binding of [3H]VP-14637. Molecular modeling analysis suggests that both molecules may bind into a small hydrophobic cavity in the inner core of F protein, interacting simultaneously with both the HR1 and HR2 domains. Altogether, these data indicate that VP-14637 and JNJ-2408068 interfere with RSV fusion through a mechanism involving a similar interaction with the F protein.

UR - http://www.scopus.com/inward/record.url?scp=21144442487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144442487&partnerID=8YFLogxK

U2 - 10.1128/AAC.49.6.2460-2466.2005

DO - 10.1128/AAC.49.6.2460-2466.2005

M3 - Article

VL - 49

SP - 2460

EP - 2466

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -